South Dakota Investment Council Sells 5,300 Shares of Illumina, Inc. $ILMN

South Dakota Investment Council lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 16.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,308 shares of the life sciences company’s stock after selling 5,300 shares during the quarter. South Dakota Investment Council’s holdings in Illumina were worth $2,593,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. Assetmark Inc. grew its holdings in shares of Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after purchasing an additional 96 shares during the last quarter. Versant Capital Management Inc boosted its position in Illumina by 8.9% in the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after buying an additional 111 shares during the period. Parkside Financial Bank & Trust grew its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares in the last quarter. Archer Investment Corp grew its stake in Illumina by 12.9% in the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after acquiring an additional 123 shares in the last quarter. Finally, Callan Family Office LLC increased its position in shares of Illumina by 4.4% during the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after acquiring an additional 124 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.60% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $128.97 on Thursday. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The firm has a market cap of $19.72 billion, a PE ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 1.45. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The stock has a fifty day moving average price of $134.74 and a 200-day moving average price of $118.89.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the topic of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Stifel Nicolaus upped their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Piper Sandler cut their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Robert W. Baird set a $137.00 price objective on Illumina in a report on Friday, February 6th. Finally, Barclays increased their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.